Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caribou BiosciencesCRBU 61 Debt-to-Equity is 0.27 as of Jun. 2026, which is 200% above its 10-year median of 0.09. GuruFocus rates CRBU with a GF Score™ of 61/100 and a GF Value™ of $1.45 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 964 Biotechnology companies, Caribou Biosciences ranks worse than 62.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Caribou Biosciences's Debt-to-Equity or its related term are showing as below:
CRBU'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07 Med: 0.09 Max: 0.27
Current: 0.27
During the past 7 years, the highest Debt-to-Equity Ratio of Caribou Biosciences was 0.27. The lowest was -0.07. And the median was 0.09.
CRBU's Debt-to-Equity is ranked worse than 62.24% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs CRBU: 0.27
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Caribou Biosciences Debt-to-Equity Related Terms
Caribou Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Caribou Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRBU vs CDXS, SPRB, MENS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Caribou Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caribou Biosciences (CRBU) has a Debt-to-Equity of 0.27 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Caribou Biosciences and its competitors. This is 200% above median its historical median of 0.09. According to the industry distribution chart, Caribou Biosciences ranks #600 out of 964 companies in the Biotechnology industry, placing it in the top 62.2%.
Is Caribou Biosciences' Debt-to-Equity too high?
Caribou Biosciences' current Debt-to-Equity of 0.27 is 200% above median its 10-year median of 0.09. The Biotechnology industry median Debt-to-Equity is 0.16. Caribou Biosciences' value of 0.27 is 74.2% above this industry median. Based on the distribution chart, Caribou Biosciences ranks #600 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caribou Biosciences has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Debt-to-Equity compare to CDXS and SPRB?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #600 out of 964 companies for Debt-to-Equity. This places Caribou Biosciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Caribou Biosciences' value of 0.27 is 74.2% above this benchmark. While the company's 10-year median is 0.09 vs. the industry median of 0.16, Caribou Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caribou Biosciences's current Debt-to-Equity of 0.27 is 74.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Debt-to-Equity is 0.27, which is 200% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.45, compared to a current price of $1.30 — trading 10.3% below its estimated fair value. The current Debt-to-Equity is 0.27, which is 200% above median its 10-year median of 0.09 and 74.2% above the Biotechnology industry median of 0.16. Caribou Biosciences' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Debt-to-Equity is 0.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued.
The current stock price of $1.30 is trading 10.3% below its estimated GF Value™ of $1.45.
GuruFocus considers Caribou Biosciences to be Modestly Undervalued.
Key valuation signals for CRBU:
Debt-to-Equity: 0.27 (200% above median its 10-year median of 0.09)
GF Value™: $1.45 vs. price of $1.30 (10.3% below fair value)
Industry Position: 74.2% above the Biotechnology median (#600 of 964)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
61GF Score
Get the complete analysis for CRBU
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
